NR-17423Fluzone?流感病毒疫苗,2008-2009年配方(疫苗）
产品图片
货号/SKU
NR-17423
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-17423?? Fluzone? Influenza Virus Vaccine, 2008-2009 Formula(Vaccines)|Influenza A & B viruses|Fluzone? Influenza Virus Vaccine, 2008-2009 Formula|2°C to 8°C|NIAID/NIHAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Fluzone? Influenza Virus Vaccine, 2008-2009 Formula, NR-17423."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
NR-17423 is an inactivated influenza virus vaccine prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid was harvested and inactivated with formaldehyde. Influenza virus was concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus was then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton? X-100) producing a "split virus". The split virus was further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.
The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended ratio of 15 ?g each of the hemagglutinin antigens from influenza viruses A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) (A/Brisbane/10/2007-like strain) and B/Florida/04/2006.
Gelatin (0.05%) was added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (≤ 100 ?g), Triton? X-100 (≤ 0.02%), and sucrose (≤ 2.0%). No thimerosal was used in the manufacturing process of the No Preservative single-dose presentations of Fluzone? vaccine.
Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2008-2009 season are now past their expiration dates.
Each syringe contains 0.5 mL of split-virus vaccine in phosphate-buffered saline and 0.05% gelatin.
NR-17423 is an inactivated influenza virus vaccine prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid was harvested and inactivated with formaldehyde. Influenza virus was concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus was then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton? X-100) producing a "split virus". The split virus was further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.
The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended ratio of 15 ?g each of the hemagglutinin antigens from influenza viruses A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) (A/Brisbane/10/2007-like strain) and B/Florida/04/2006.
Gelatin (0.05%) was added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (≤ 100 ?g), Triton? X-100 (≤ 0.02%), and sucrose (≤ 2.0%). No thimerosal was used in the manufacturing process of the No Preservative single-dose presentations of Fluzone? vaccine.
Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2008-2009 season are now past their expiration dates.
Each syringe contains 0.5 mL of split-virus vaccine in phosphate-buffered saline and 0.05% gelatin.
主要内容
此项目的每个订单数量限制为1.此项目每年可订购两次.在这一限制下订单将在发货前发送到NIAID进行批准. NR-17423是由流感病毒在胚胎鸡蛋中繁殖的灭活流感病毒疫苗.用甲醛收获含有病毒的含糊的液体并灭活.使用连续流动离心机浓缩流感病毒并在线性蔗糖密度梯度溶液中纯化.然后使用非离子表面活性剂，聚乙二醇P-异辛基苯基醚（Triton ? x-100）化学破坏病毒，产生“分裂病毒”.进一步纯化分裂病毒，然后悬浮在磷酸钠缓冲的等渗氯化钠溶液中. 根据美国公共卫生服务要求标准化血凝素含量.每个0.5mL注射器含有来自流感病毒A / Brisbane / 59/2007（H1N1），A / uruguay / 716/2007（H3N2）的每种血血糖素抗原的建议比为15μg血凝素抗原（A / Brisbane / 10/2007菌株）和B / Florida / 04/2006. 加入明胶（0.05％）作为稳定剂加入.每种0.5ml剂量可含有残留量的甲醛（≤100μg），Triton ? x-100（≤0.02％）和蔗糖（≤2.0％）.在氟氮酮?疫苗的无防腐单剂量介绍的制造过程中没有使用硫氏菌属. 请注意，此疫苗准备是释放用于研究使用而不是人类使用. 2008-2009赛季生产的疫苗现在已经过到期日期. 每个注射器含有0.5ml磷酸盐缓冲盐水和0.05％明胶的分裂病毒疫苗.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2024-01-21
2021-12-21
2022-04-01
2021-12-21
2020-06-09
2024-05-19
2020-08-04
2022-04-01
2022-04-01
2024-08-16
2022-04-01
2022-01-10
2021-12-21
2022-04-01
2022-04-01